Integra LifeSciences Shares Surge On Q3 Beat

  • Integra LifeSciences Holdings Corp IART reported Q3 FY22 sales of $385.19 million, -0.4% Y/Y on a reported basis, and +3.5% organic, beating the consensus of $381.24 million.
  • Adjusted EPS stood at $0.86, ahead of the Street estimate of $0.73.
  • Adjusted gross margin was 66.7%, compared to 68.3% in the prior year.
  • Adjusted EBITDA was $105.3 million, or 27.3% of revenue, compared to $104.3 million, or 27.0% of revenue, in the prior year.
  • The company completed the sale of its non-core traditional wound care business at the end of August 2022.
  • Guidance: For FY22, Integra Lifescience sees revenue of $1.551-$1.563 billion (prior view $1.548-$1.566 billion). 
  • The guidance considers the macro environment, continuing supply constraints, and potential adjustments to the CereLink reserve.
  • The company raised FY22 adjusted EPS to $3.29-$3.33 vs. the earlier outlook of $3.12-$3.20 and the consensus of $3.15.
  • For Q4, IART expects sales of $391-$403 million vs. the consensus of $403.5 million. It sees adjusted EPS of $0.87-$0.91 (consensus of $0.88).
  • Price Action: IART shares are up 5.43% at $47.02 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!